Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ESRRG | P62508 | 6/20 | 0.45 |
| ▸ | ESRRB | O95718 | 4/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4653287 | 0.99 | HRH3 (0.50) | HRH3KCNH2TSHRHSD17B10KDM4E | |
| SCHEMBL23993217 | 0.92 | ESRRG (0.46) | HRH3KCNH2TSHRHSD17B10KDM4E | |
| SCHEMBL25005730 | 0.85 | KDM4E (0.47) | TSHRHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL63894 | 0.83 | HDAC3 (0.54) | TSHRHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL25453173 | 0.83 | HRH3 (0.55) | HRH3KCNH2ALDH1A1ESRRGESRRB | |
| SCHEMBL1306328 | 0.83 | KCNH2 (0.58) | HRH3KCNH2ALDH1A1ESRRGESRRB | |
| SCHEMBL27392372 | 0.83 | NAMPT (0.56) | KCNH2TSHRHSD17B10KDM4EALDH1A1 | |
| SCHEMBL23384133 | 0.82 | HRH3 (0.51) | HRH3KCNH2ESRRGESRRBESR1 | |
| SCHEMBL13267179 | 0.82 | ALDH1A1 (0.55) | TSHRHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL16304063 | 0.82 | KCNH2 (0.54) | HRH3KCNH2ESRRGESRRBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| EP-3725777-A1 | BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-1254124-B1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191392-A1 | DIPEPTIDE NITRILE CATHESPIN K INHIBITORS | NORVARTIS AG (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | NORVARTIS AG (CH) | 2005-12-01 | — | — | US | disclosed |
| US-6642239-B2 | Compounds such as N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(piperazin-1-yl)-benzamide | NOVARTIS AG (CH) | 2003-11-04 | — | — | US | disclosed |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | MISSBACH MARTIN (CH) | 2003-10-30 | — | — | US | disclosed |
| EP-1254124-A1 | DIPEPTIDE NITRILE CATHPSIN K INHIBITORS | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
| WO-2001058886-A1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | HRH3 239/4885KCNH2 2664/4885TSHR 3453/4885 |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSL, CTSV | HRH3 137/4885KCNH2 2680/4885TSHR 2008/4885 |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | PDXK, MAP4K2, PLK2 | HRH3 4015/4885KCNH2 3042/4885TSHR 3763/4885 |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | HRH3 239/4885KCNH2 2664/4885TSHR 3453/4885 |
| US-20070191392-A1 | DIPEPTIDE NITRILE CATHESPIN K INHIBITORS | CTSL, CTSK, CTSC | HRH3 269/4885KCNH2 2572/4885TSHR 2525/4885 |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | HRH3 4015/4885KCNH2 4599/4885TSHR 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.